Lyell Immunopharma

Historical price data

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies with the goal of delivering lasting remissions or cures for patients with cancer. The company's approach combines novel CAR constructs, proprietary manufacturing protocols, and T-cell biology insights to generate more potent and persistent T cells. Its lead candidate, ronde-cel, is in pivotal trials for large B-cell lymphoma, while LYL273 is in Phase 1 for metastatic colorectal cancer, representing a significant push into solid tumors. Lyell is a fully integrated company with in-house research, development, and manufacturing capabilities.

A next-generation CAR T-cell platform combining novel dual-targeting CAR constructs with proprietary manufacturing processes that enrich for CD62L+ T cells (naive/central memory phenotypes) to enhance persistence, reduce exhaustion, and improve anti-tumor potency.

6 drugs in pipeline, 1 in Phase 3

Lyell faces competition from major pharmaceutical companies with approved CAR T therapies (Gilead/Kite, Bristol Myers Squibb, Novartis) in lymphoma and from numerous biotechs in solid tumors. Its differentiation lies in its dual-targeting CAR constructs and proprietary manufacturing process designed to produce more persistent and less exhausted T cells.